Nausea, mild abdominal discomfort, and occasional vomiting are frequent, usually mild to moderate, and typically improve over several weeks as the body adjusts to the medication
Lancet Diabetes Endocrinol 2018;6:10513.ArticlePubMed 48
Neurotherapeutics 18 , 962978 (2021)
These results support findings from other recent trials , showing that these drugs used for type 2 diabetes are worth exploring in type 1 diabetics, said Ahmad Haidar , a diabetes researcher at McGill University in Canada, who was not involved in the study
Medicare Part D coverage for obesity medications has expanded, though specific formulary placement varies by plan
New England Journal of Medicine, 387 (3), 205216